MRI and Clinical Disease Activity in Patients Treated Long Term With Natalizumab
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 06 Oct 2017
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Sponsors Biogen
- 02 Oct 2017 Planned End Date changed from 30 Jun 2017 to 31 Dec 2017.
- 02 Oct 2017 Planned primary completion date changed from 30 Jun 2017 to 31 Dec 2017.
- 17 Sep 2016 Results of interim analysis (n=162) of czech cohort was presented at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis